Compare AbCellera Biologics Inc (ABCL) vs Global X Robotics and Artificial Intelligence ETF (BOTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Global X Robotics and Artificial Intelligence ETF — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Global X Robotics and Artificial Intelligence ETF trades at $35.9. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | BOTZ | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $41.63 |
52-Week Low | $2.78 | $31.99 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BOTZ trades at $36.59, down 2.14% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF focuses on robotics and AI, benefiting from reshoring trends and AI's expansion into physical automation. Recent news highlights robotics as the next trillion-dollar AI theme, with strong media coverage positioning BOTZ as a key player in the humanoid robotics and industrial automation space.
Outlook remains positive due to structural growth in robotics and AI, though valuation metrics are unavailable. Risks include sector concentration and reliance on AI adoption pace. Analyst sentiment is generally favorable, with the ETF well-positioned for long-term automation trends but vulnerable to tech sector volatility and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →
